110 related articles for article (PubMed ID: 10918602)
1. A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation.
Arlt DH; Baur B; Wagner B; Höppner W
Oncogene; 2000 Jul; 19(30):3445-8. PubMed ID: 10918602
[TBL] [Abstract][Full Text] [Related]
2. The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein.
Bongarzone I; Vigano E; Alberti L; Mondellini P; Uggeri M; Pasini B; Borrello MG; Pierotti MA
Oncogene; 1999 Aug; 18(34):4833-8. PubMed ID: 10490816
[TBL] [Abstract][Full Text] [Related]
3. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
[TBL] [Abstract][Full Text] [Related]
4. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
[TBL] [Abstract][Full Text] [Related]
5. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.
Chappuis-Flament S; Pasini A; De Vita G; Ségouffin-Cariou C; Fusco A; Attié T; Lenoir GM; Santoro M; Billaud M
Oncogene; 1998 Dec; 17(22):2851-61. PubMed ID: 9879991
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
[TBL] [Abstract][Full Text] [Related]
7. Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases.
Kato M; Iwashita T; Takeda K; Akhand AA; Liu W; Yoshihara M; Asai N; Suzuki H; Takahashi M; Nakashima I
Mol Biol Cell; 2000 Jan; 11(1):93-101. PubMed ID: 10637293
[TBL] [Abstract][Full Text] [Related]
8. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
9. Grb2 binding to the different isoforms of Ret tyrosine kinase.
Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA
Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818
[TBL] [Abstract][Full Text] [Related]
10. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
11. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.
Pelet A; Geneste O; Edery P; Pasini A; Chappuis S; Atti T; Munnich A; Lenoir G; Lyonnet S; Billaud M
J Clin Invest; 1998 Mar; 101(6):1415-23. PubMed ID: 9502784
[TBL] [Abstract][Full Text] [Related]
12. Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation.
Bongarzone I; Vigano E; Alberti L; Borrello MG; Pasini B; Greco A; Mondellini P; Smith DP; Ponder BA; Romeo G; Pierotti MA
Oncogene; 1998 May; 16(18):2295-301. PubMed ID: 9620546
[TBL] [Abstract][Full Text] [Related]
13. Osmotic stress-mediated activation of RET kinases involves intracellular disulfide-bonded dimer formation.
Takeda K; Kato M; Wu J; Iwashita T; Suzuki H; Takahashi M; Nakashima I
Antioxid Redox Signal; 2001 Jun; 3(3):473-82. PubMed ID: 11491658
[TBL] [Abstract][Full Text] [Related]
14. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
15. RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2.
Lorenzo MJ; Gish GD; Houghton C; Stonehouse TJ; Pawson T; Ponder BA; Smith DP
Oncogene; 1997 Feb; 14(7):763-71. PubMed ID: 9047383
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain.
Sánchez B; Robledo M; Biarnes J; Sáez ME; Volpini V; Benítez J; Navarro E; Ruiz A; Antiñolo G; Borrego S
J Med Genet; 1999 Jan; 36(1):68-70. PubMed ID: 9950371
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
[TBL] [Abstract][Full Text] [Related]
18. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
[TBL] [Abstract][Full Text] [Related]
19. A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A.
Höppner W; Ritter MM
Hum Mol Genet; 1997 Apr; 6(4):587-90. PubMed ID: 9097963
[TBL] [Abstract][Full Text] [Related]
20. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]